|1.||Quindós, Guillermo: 12 articles (10/2014 - 03/2005)|
|2.||Walsh, Thomas J: 8 articles (12/2014 - 12/2002)|
|3.||Herbrecht, Raoul: 7 articles (03/2015 - 04/2003)|
|4.||Singh, Nina: 7 articles (09/2013 - 03/2003)|
|5.||Kontoyiannis, Dimitrios P: 7 articles (05/2010 - 12/2003)|
|6.||Donnelly, J Peter: 6 articles (10/2015 - 06/2008)|
|7.||Marchetti, Oscar: 6 articles (03/2015 - 01/2007)|
|8.||Lewis, Russell E: 6 articles (08/2011 - 08/2002)|
|9.||Patterson, Thomas F: 5 articles (10/2015 - 11/2005)|
|10.||Lass-Flörl, Cornelia: 5 articles (07/2015 - 10/2005)|
|1.||Amphotericin B (Amphotericin)FDA LinkGeneric
03/01/2009 - "Amphotericin B (AmB) is the gold standard of antifungal treatment for the most severe invasive mycoses. "
12/01/2000 - "Amphotericin B is the gold standard for antifungal treatment for the most severe mycoses. "
10/01/2003 - "Amphotericin B by various routes is the mainstay of treatment for life-threatening and severe ophthalmic mycoses. "
08/01/1995 - "Amphotericin B (AmB) is widely used for the treatment of systemic mycoses. "
02/01/1985 - "This required choosing of the dose and regimen for the use of amphotericin B, the only drug effective in the treatment of generalized mycoses. "
|2.||Itraconazole (Sporanox)FDA LinkGeneric
02/01/1990 - "Oral itraconazole is effective in the treatment of mycoses. "
01/01/1987 - "These results indicate that itraconazole is effective in treating these recalcitrant superficial mycoses and should be assessed in a larger unselected group of patients and compared with alternative drugs."
12/01/2003 - "Oral itraconazole may provide a safe and effective alternative for patients with locally invasive non-disseminated mycoses due to Curvularia species."
11/01/2000 - "The efficacy of i.v. itraconazole in these animal models justifies its further investigation for the treatment of life-threatening mycoses in humans."
12/01/1996 - "The efficacy of oral itraconazole 2 x 200 mg capsules daily for prevention of systemic mycoses was investigated in granulocytopenic patients with haematological malignancies. "
05/01/2000 - "Surgical resection, in combination with antifungal agents, is a safe and effective form of therapy for invasive mycoses. "
06/01/2006 - "The availability of new antifungal agents with novel mechanisms of action and improved tolerability has widened the possibilities for combination therapy for difficult-to-treat opportunistic mycoses. "
07/01/2004 - "The availability of new antifungal agents with unique mechanisms of action and improved tolerability has widened the possibilities for the use of combination antifungal therapy for difficult-to-treat opportunistic mycoses. "
01/01/2003 - "Development of new antifungal agents and combination therapies may result in improvement in the management of subcutaneous mycoses in the future."
08/01/2006 - "Antifungal combinations are increasingly used in clinical practice to improve outcomes for refractory mycoses because of the suboptimal efficacy of current antifungal agents. "
|4.||Fluconazole (Zonal)FDA LinkGeneric
11/01/1995 - "A clinical study was conducted to test the efficacy of fluconazole in the treatment of tropical deep mycoses. "
03/01/1992 - "Eighty-eight immunocompetent patients with deep mycoses from eight countries were evaluated with the same protocol for efficacy of fluconazole monotherapy. "
05/23/2000 - "To study the therapy, efficacy and safety of fluconazole in candidal mycoses during neonatal phase and infancy a case review in 53 newborns and infants was performed. "
09/01/1997 - "The possible adverse effects of chronic, high-dose fluconazole therapy are detailed from analysis of a multicenter, dose-escalating study of the therapy of invasive mycoses. "
04/01/1997 - "The purpose of this prospective, open-label, noncomparative, multicentre study was to evaluate the efficacy and safety of fluconazole in the treatment of hospitalised patients with mycoses. "
|5.||Ketoconazole (Nizoral)FDA LinkGeneric
07/01/1982 - "Ketoconazole is effective in suppressing disease in various mycoses. "
05/01/1986 - "Treatment of systemic mycoses with ketoconazole: studies of ketoconazole serum levels."
07/01/2015 - "Today, oral ketoconazole is only indicated for endemic mycoses, where alternatives are not available or feasible. "
07/01/2015 - "Ketoconazole was the first broad-spectrum oral antifungal agent available to treat systemic and superficial mycoses. "
03/01/2004 - "For almost a decade, ketoconazole was regarded as the drug of choice in nonlife-threatening endemic mycoses. "
|6.||terbinafine (Lamisil)FDA LinkGeneric
05/01/2010 - "To evaluate the in vitro efficacy of terbinafine activity against filamentous fungi and yeasts that cause mycoses. "
05/01/2010 - "Evaluation of the disk-diffusion method to determine the in vitro efficacy of terbinafine against subcutaneous and superficial mycoses agents."
01/01/2015 - "Unfortunately, no compound exhibited efficacy comparable with that of terbinafine, which is the most widely used agent for treating mycoses caused by dermatophytes. "
12/01/2011 - "Our results provide evidence supporting the use of terbinafine as an oral therapeutic agent for treating systemic and subcutaneous mycoses in dogs."
02/01/2008 - "We review the current literature with regard to in vitro data and clinical experience with terbinafine in the treatment of rare and refractory mycoses."
|7.||liposomal amphotericin BFDA Link
12/01/1998 - "However, despite administration of liposomal amphotericin-B culture-proven mycoses were associated with a high morbidity (93,3%). "
01/01/1996 - "Amphotericin B Lipid Complex (Abelcet) in the treatment of invasive mycoses: the North American experience."
06/01/1994 - "Treatment of deep mycoses with liposomal amphotericin B."
05/01/1992 - "Ambisome could represent an important advance in antifungal treatment since it allows aggressive treatment and eradication of mycoses refractory to conventional therapy while avoiding renal toxicity."
02/01/1997 - "Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses."
05/01/1992 - "Phase II study of the therapeutic efficacy and safety of the new antimycotic sertaconazole in the treatment of superficial mycoses caused by Candida albicans."
06/01/2005 - "Various studies carried out in animal models, clinical and toxicologic trials have confirmed the value of sertaconazole in the topical treatment of superficial mycoses in dermatology and gynecology. "
05/01/1992 - "In a randomized, parallel, double-blind trial, the activity of sertaconazole cream was studied in 20 patients suffering from superficial mycoses caused by dermatophytes, confirmed by microscopic examination (KOH) and culture test. "
05/01/1992 - "Study on the sensitizing capacity of the new antimycotic sertaconazole in the treatment of cutaneous mycoses."
01/01/2009 - "Sertaconazole was generally well tolerated in patients with dermatological and gynaecological mycoses. "
|9.||micafungin (FK463)FDA Link
03/31/2009 - "Micafungin is a new and very useful pharmacological tool for the treatment of invasive mycoses with a wide antifungal spectrum for the most common pathogenic fungi. "
06/01/2004 - "Micafungin is quite useful in the treatment of deep mycoses. "
07/18/2002 - "Micafungin is currently in phase III clinical trials worldwide as a parenteral agent for various mycoses, and a new drug application (NDA) was recently filed in Japan."
09/01/2013 - "Targeted prophylaxis with micafungin or ABLC decreased the risk of mycoses in high-risk recipients compared with that in low-risk recipients. "
03/31/2009 - "[Future role of micafungin in the treatment of invasive mycoses caused by filamentous fungi]."
|10.||voriconazole (Vfend)FDA LinkGeneric
09/01/2000 - "Voriconazole has shown promise in the treatment of superficial and systemic mycoses. "
09/30/2007 - "This monography presents the most relevant studies on the present situation of invasive mycoses, its diagnosis and treatment, as well as data confirming the important role of voriconazole in their treatment."
01/01/2007 - "Objectives of the present study were to develop new, simple analytical methods and to assess variability of voriconazole blood levels in patients with invasive mycoses. "
06/01/2003 - "These murine studies support expansion of voriconazole therapy in other highly resistant systemic mycoses."
01/01/1998 - "These results suggest that voriconazole has a wide spectrum of activity in vitro; its effectiveness in the treatment of human mycoses is under evaluation in clinical trials."
|1.||Drug Therapy (Chemotherapy)
12/01/2013 - "Photodynamic chemotherapy in the treatment of superficial mycoses: an evidence-based evaluation."
11/01/2012 - "We review the current treatments available for superficial mycoses and discuss recent developments in pharmacotherapy and the most useful adjuvant treatments. "
05/01/2011 - "Natural chemosensitizing agents could lower dosages needed for effective chemotherapy of invasive mycoses. "
07/18/2008 - "The potential use of natural, safe chemosensitizing agents in antifungal chemotherapy of human mycoses as an alternative to combination therapy is discussed."
06/01/2006 - "Despite recent additions to our antifungal drug armamentarium, success rates for many mycoses remain unacceptably low and antifungal drug therapy is often limited by toxicity, resistance and high cost. "
10/15/2004 - "Epidemiological characteristics of invasive mycoses in organ transplant recipients have evolved sufficiently to warrant thoughtful reconsideration of the subsets of patients and the fungal pathogens to be targeted for antifungal prophylactic trials in the current era. "
08/01/2014 - "Opportunistic deep cutaneous mycoses in solid organ transplant recipients."
08/01/2014 - "Opportunistic deep cutaneous mycoses in solid organ transplant recipients."
05/01/2010 - "Incidence and clinical predictors of primary opportunistic deep cutaneous mycoses in solid organ transplant recipients: a multicenter cohort study."
06/01/2008 - "Moreover, the incidence of invasive mycoses varies in the different post transplant phases. "
|3.||Transplantation (Transplant Recipients)
04/01/2014 - "This 5-year multicenter prospective surveillance study found that endemic mycoses occur uncommonly in SOT and HCT recipients, and that the period at risk extends for years after transplantation."
06/01/2015 - "Other fungi including the mucorales, Cryptococcus and endemic mycoses are emerging pathogens but data regarding incidence and timing of disease in intestinal and multivisceral transplant recipients are lacking. "
11/01/2010 - "Challenges and prospects of adoptive immunotherapy in prevention and treatment of opportunistic mycoses in hematologic transplant recipients."
05/01/2010 - "Primary deep cutaneous opportunistic mycoses in OTR occur mainly in the first two yr after transplantation, in renal transplant recipients, and in older patients."
05/01/2010 - "Twenty-two cases of deep cutaneous mycoses were detected, (IR 1.2 cases per 1000 PYs) after a mean follow-up time since transplantation of 2.5 yr +/- 2.0 SD (median 1.8 yr). "
|5.||Stem Cell Transplantation
01/01/2006 - "Furthermore, in comparing the rate of mycoses in recipients of stem cell transplantation with that of non-recipients, that of recipients was about 10% higher. "
11/01/2000 - "With the increasing use of aggressive chemotherapy and stem cell transplantation causing profound, prolonged depressed immunity, the risk of invasive mycoses has increased. "
01/01/2011 - "Forty-four allogeneic stem cell transplantation recipients diagnosed with probable or proven IA according to the criteria of the European Organization for Research and Treatment of Cancer/Mycoses Study Group, were enrolled. "
09/01/2001 - "Opportunistic mycoses have emerged as important causes for morbidity and mortality in pediatric cancer patients, particularly in those with intensively treated hematological malignancies, allogeneic hematopoetic stem cell transplantation, and aplastic anemia. "